Bladder Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Bladder cancer is the 10th most common cancer globally, with approximately 600,000 new cases annually. Around 90% are urothelial carcinoma (formerly transitional cell carcinoma), arising from the epithelial lining of the bladder. Treatment strategy is determined primarily by tumor stage at diagnosis. Non-muscle-invasive bladder cancer (NMIBC), comprising roughly 75% of new cases, includes stages Ta (papillary, confined to urothelium), T1 (invading lamina propria), and carcinoma in situ (CIS). Standard NMIBC treatment is transurethral resection of bladder tumor (TURBT), which serves as both diagnostic and therapeutic, followed by intravesical instillation of BCG (Bacillus Calmette-Guérin) for high-risk disease or mitomycin C / gemcitabine for intermediate risk. Muscle-invasive bladder cancer (MIBC, stages T2–T4) accounts for 25% of cases and requires systemic treatment. The gold standard is neoadjuvant cisplatin-based chemotherapy (GC or MVAC regimen) followed by radical cystectomy with urinary diversion. An alternative bladder-preserving trimodality therapy (TMT) combines maximal TURBT, concurrent chemoradiation, and is appropriate for selected patients. Metastatic urothelial carcinoma is managed with platinum-based chemotherapy, and now increasingly with pembrolizumab (checkpoint inhibitor) and the antibody-drug conjugate enfortumab vedotin plus pembrolizumab (EV-P), which has demonstrated superior overall survival over chemotherapy in first-line cisplatin-ineligible disease. Surveillance with cystoscopy every 3–6 months is critical given the high recurrence rate of NMIBC.

Bladder cancer treatment addresses a spectrum of urothelial and non-urothelial malignancies. Non-muscle-invasive bladder cancer encompasses stage Ta papillary tumors, T1 tumors invading the lamina propria (including high-grade T1 at elevated risk of progression), and CIS — a flat, high-grade lesion with 30–50% risk of progressing to MIBC without treatment. Muscle-invasive bladder cancer (T2: superficial muscle; T3: deep muscle/perivesical fat; T4: adjacent organs) requires aggressive systemic plus surgical or radiation management. Upper tract urothelial carcinoma (ureter, renal pelvis) is a related condition managed with nephroureterectomy and similar chemotherapy regimens. Recurrent NMIBC failing BCG therapy (BCG-unresponsive disease) is a critical clinical scenario requiring salvage options including pembrolizumab, nadofaragene firadenovec, or cystectomy. Metastatic urothelial carcinoma (visceral or bone metastases) is managed with systemic therapy. Variant histologies including squamous cell carcinoma (more common in schistosomiasis-endemic regions) and adenocarcinoma require histology-specific approaches and are less responsive to standard urothelial carcinoma regimens.

TURBT is indicated for all NMIBC and is performed under spinal or general anesthesia, usually as an outpatient or overnight procedure. BCG immunotherapy is appropriate for high-risk NMIBC — including T1 high-grade, CIS, large or multifocal Ta high-grade tumors — and requires an immunocompetent patient; it is contraindicated in active tuberculosis, significant immunosuppression, traumatic catheterization, or symptomatic UTI at instillation. Radical cystectomy candidacy requires adequate performance status (ECOG 0–2), no distant metastases, and acceptable organ function for recovery from major surgery. Neoadjuvant cisplatin-based chemotherapy eligibility requires eGFR >45 mL/min, ECOG performance status 0–1, no grade ≥3 peripheral neuropathy, and no symptomatic congestive heart failure. Bladder-preserving trimodality therapy is appropriate for patients who refuse cystectomy, are medically inoperable, have a solitary tumor without associated CIS, and can achieve a complete TURBT. Immunotherapy (pembrolizumab, enfortumab vedotin) eligibility involves PD-L1 testing (CPS score), renal function, and absence of severe autoimmune conditions. Pre-treatment workup includes cystoscopy with biopsy, CT urogram or MRI pelvis, urine cytology, chest imaging, and complete blood count with metabolic panel.

Treatment selection is stage-driven and personalised to each patient's fitness, anatomy, and preferences. For non-muscle-invasive bladder cancer (NMIBC), transurethral resection of bladder tumor (TURBT) is the primary intervention, performed under spinal or general anaesthesia through a rigid cystoscope. High-risk NMIBC then receives intravesical BCG immunotherapy: induction (6 weekly instillations) followed by maintenance (SWOG protocol: 3-week courses at 3, 6, 12, 18, 24, 30, and 36 months). BCG-unresponsive CIS can be treated with nadofaragene firadenovec (Adstiladrin), pembrolizumab, or clodronate-containing regimens. Intermediate-risk NMIBC is managed with a single post-operative instillation of mitomycin C or gemcitabine. For muscle-invasive bladder cancer (MIBC), neoadjuvant cisplatin-based chemotherapy (gemcitabine-cisplatin or dose-dense MVAC) is delivered before radical cystectomy. Radical cystectomy involves removal of the bladder, prostate/uterus, and regional lymph nodes, with urinary reconstruction via ileal conduit, orthotopic neobladder, or continent cutaneous reservoir. Bladder-preserving trimodality therapy (TMT) combines maximal TURBT, concurrent chemoradiation (cisplatin, gemcitabine), and radiation to 64 Gy, achieving 5-year bladder-intact survival of 40–50% in selected patients. For metastatic urothelial carcinoma, the enfortumab vedotin plus pembrolizumab combination (EV-302 trial) is now first-line for cisplatin-ineligible patients, with median overall survival of 31.5 months versus 16.1 months with chemotherapy. Ejaculatory duct obstruction causing haematospermia may be addressed endoscopically by transurethral resection of the ejaculatory ducts (TURED). For BCG-unresponsive carcinoma in situ, nadofaragene firadenovec (gene therapy delivering interferon alpha-2b) delivers complete response in 53% at 3 months in pivotal trials.

BCG immunotherapy for high-risk NMIBC improves recurrence-free survival by 30–40% compared to TURBT alone and reduces progression to MIBC by 10–20% in landmark meta-analyses. Induction BCG followed by maintenance (SWOG protocol: 3-week maintenance courses at 3, 6, 12, 18, 24, 30, and 36 months) provides superior durable protection. Radical cystectomy offers a 5-year overall survival of 50–60% for cisplatin-eligible MIBC patients. Neoadjuvant MVAC chemotherapy improves 5-year overall survival from 48% to 57% compared to cystectomy alone (SWOG 8710 trial). Trimodality therapy achieves 5-year bladder-intact survival of 40–50% and overall survival comparable to cystectomy in carefully selected patients (RTOG trials). In metastatic disease, the enfortumab vedotin plus pembrolizumab combination (EV-P) demonstrated a median overall survival of 31.5 months versus 16.1 months with standard chemotherapy in cisplatin-ineligible patients (EV-302/KEYNOTE-A39 trial), establishing a new first-line standard. Pembrolizumab monotherapy in second-line treatment extends overall survival versus chemotherapy in KEYNOTE-045. BCG-unresponsive CIS treated with nadofaragene firadenovec achieves complete response in 53% at 3 months.

TURBT carries a low but real risk of bladder perforation (less than 1%), significant hematuria requiring irrigation (2–3%), and obturator nerve reflex during resection of lateral wall tumors, which can cause inadvertent bladder perforation — managed with general anesthesia or spinal block with muscle relaxant. Intravesical BCG causes chemical cystitis in approximately 90% of patients (usually self-limiting, resolving within 48 hours), and systemic BCG sepsis — a rare but life-threatening complication occurring in less than 0.5% — requires prompt cessation and anti-tuberculous therapy (isoniazid, rifampicin). Radical cystectomy carries a 90-day major complication rate of 25–30%, including wound complications, ileus, uretero-enteric anastomotic leaks, and urinary diversion complications (ileal conduit, orthotopic neobladder, or continent cutaneous reservoir). Sexual dysfunction occurs in 70–90% of men and approximately 50% of women following standard cystectomy; nerve-sparing techniques reduce but do not eliminate this risk. Perioperative mortality is 1–3% at experienced centers. Checkpoint inhibitor immunotherapy (pembrolizumab, atezolizumab) produces immune-related adverse events — colitis, pneumonitis, hepatitis, and endocrinopathies — in approximately 15–25% of patients at grade 3–4 severity, requiring immunosuppression with systemic corticosteroids. Enfortumab vedotin adds peripheral neuropathy and skin reactions as class-specific toxicities.

Bladder cancer has one of the highest recurrence rates of any solid tumor, making surveillance essential. After TURBT for NMIBC, cystoscopy is performed at 3 months post-operatively, then every 3–6 months for 2 years (high-risk: 3-monthly; low-risk: 6-monthly), then annually for life. Urine cytology accompanies cystoscopy for high-grade disease. CT urogram or MRI evaluates the upper tract at 12-month intervals for high-risk patients, given the 5–10% risk of upper tract urothelial carcinoma. After radical cystectomy for MIBC, follow-up includes cross-sectional imaging (CT chest, abdomen, pelvis) every 3–6 months for 2 years, then 6-monthly to 5 years, then annually. Serum metabolic panel (vitamin B12, electrolytes, renal function, alkaline phosphatase) monitors urinary diversion function and nutritional absorption. Patients with orthotopic neobladder need periodic urodynamic assessment for voiding efficiency. After trimodality therapy (TMT), cystoscopy with biopsy is mandatory at 3 months to confirm complete response; CT imaging follows standard MIBC surveillance. PSA monitoring is required in men who had prostate-sparing cystectomy variants.

Bladder cancer treatment costs span a wide range depending on stage and modality. TURBT (transurethral resection): India $1,500–4,000; USA $5,000–15,000; UK £3,000–8,000. Intravesical BCG (full induction course of 6 weekly instillations): India $200–800; USA $1,000–3,000 (note: BCG has experienced supply shortages affecting US availability and price). Radical cystectomy with urinary diversion: India $6,000–15,000; Thailand $15,000–30,000; Turkey $8,000–18,000; Mexico $12,000–25,000; USA $40,000–100,000; UK £25,000–50,000 (private). Pembrolizumab (per cycle, 3-weekly): India $2,000–5,000 (including biosimilar/generic access programs); USA $8,000–12,000. Enfortumab vedotin + pembrolizumab combination: USA $20,000–30,000 per cycle before insurance. Annual cystoscopic surveillance adds $1,000–3,000 per year in India and $5,000–10,000 per year in the USA. Medical tourism to India, Thailand, or Turkey offers significant savings on surgical costs with JCI-accredited hospitals maintaining international standards.

For NMIBC, patients who cannot tolerate BCG (due to immunosuppression, active TB, or severe BCG cystitis) may use intravesical mitomycin C, gemcitabine, or docetaxel as alternatives. Device-assisted intravesical therapy using electromotive drug administration (EMDA-mitomycin C) or hyperthermic intravesical chemotherapy (HIVEC) improves drug penetration and recurrence-free survival in high-risk NMIBC. For MIBC, patients unsuitable for cystectomy may undergo definitive chemoradiation (radiation alone if chemotherapy is contraindicated). Immunotherapy with pembrolizumab or atezolizumab is available for cisplatin-ineligible patients with PDL1-positive tumors as first-line systemic treatment. Novel targeted therapies include erdafitinib (FGFR3 inhibitor) for FGFR3-mutated urothelial carcinoma and sacituzumab govitecan (Trop-2 antibody-drug conjugate) in later lines. Active surveillance (watchful waiting) is occasionally appropriate for low-grade, low-risk Ta tumors in elderly frail patients where treatment burden outweighs benefit.